Price (delayed)
$1.34
Market cap
$82.06M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.47
Enterprise value
$69.58M
Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual ...
Highlights
The company's quick ratio fell by 38% YoY but it rose by 6% QoQ
The revenue has dropped by 100% year-on-year
PLRX's gross profit has dropped by 100% year-on-year
Key stats
What are the main financial stats of PLRX
MarketValuationsEarnings
Shares outstanding
61.24M
Market cap
$82.06M
Enterprise value
$69.58M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.27
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$228.37M
Net income
-$210.3M
EBIT
-$207.28M
EBITDA
-$201.7M
Free cash flow
-$159.35M
Per shareBalance sheetLiquidity
EPS
-$3.47
EPS diluted
-$3.47
Free cash flow per share
-$2.63
Book value per share
$5
Revenue per share
$0
TBVPS
$6.56
Total assets
$396.95M
Total liabilities
$92.87M
Debt
$60.19M
Equity
$304.08M
Working capital
$329.05M
Debt to equity
0.2
Current ratio
10.91
Quick ratio
10.75
Net debt/EBITDA
0.06
MarginsEfficiencyDividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-45.5%
Return on equity
-56.8%
Return on invested capital
-51.9%
Return on capital employed
-57%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PLRX stock price
How has the Pliant Therapeutics stock price performed over time
Intraday
2.29%
1 week
-8.84%
1 month
-0.74%
1 year
-90.79%
YTD
-89.83%
QTD
-0.74%
Financial performance
How have Pliant Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$228.37M
Net income
-$210.3M
Gross margin
N/A
Net margin
N/A
PLRX financials
The revenue has dropped by 100% year-on-year
PLRX's gross profit has dropped by 100% year-on-year
The net income has contracted by 30% YoY and by 4.3% from the previous quarter
PLRX's operating income is down by 24% year-on-year and by 2.8% since the previous quarter
Growth
What is Pliant Therapeutics's growth rate over time
PLRX growth chart
Valuation
What is Pliant Therapeutics stock price valuation
P/E
N/A
P/B
0.27
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Price to earnings (P/E)
The EPS has declined by 26% year-on-year and by 3.9% since the previous quarter
Price to book (P/B)
PLRX's price to book (P/B) is 90% lower than its 5-year quarterly average of 2.7 and 87% lower than its last 4 quarters average of 2.1
The equity has contracted by 36% YoY and by 12% from the previous quarter
Price to sales (P/S)
The revenue has dropped by 100% year-on-year
Efficiency
How efficient is Pliant Therapeutics business performance
The ROE has dropped by 82% year-on-year and by 16% since the previous quarter
Pliant Therapeutics's return on assets has shrunk by 57% YoY and by 11% QoQ
The company's return on invested capital has shrunk by 53% YoY and by 9% QoQ
Dividends
What is PLRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PLRX.
Financial health
How did Pliant Therapeutics financials performed over time
Assets vs liabilities
The total liabilities has soared by 141% YoY but it has contracted by 7% from the previous quarter
Pliant Therapeutics's current ratio has decreased by 38% YoY but it has increased by 6% from the previous quarter
Debt vs equity
Pliant Therapeutics's debt is 80% lower than its equity
The equity has contracted by 36% YoY and by 12% from the previous quarter
PLRX's debt to equity is up by 18% since the previous quarter
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from 
and Sharadar.